Prothena Corporation plc is a late-stage clinical biotechnology company dedicated to developing therapies for devastating neurodegenerative and rare peripheral amyloid diseases. The company's business model centers on leveraging its deep expertise in protein dysregulation and misfolded protein biology to discover and advance novel monoclonal antibodies. Prothena's pipeline includes both wholly owned and partnered programs. Key clinical candidates include birtamimab for the treatment of AL amyloidosis, prasinezumab for Parkinson's disease (partnered with Roche), coramitug for ATTR amyloidosis (partnered with Novo Nordisk), and PRX012 for Alzheimer's disease. The company generates revenue primarily through strategic collaborations, receiving upfront payments, research and development funding, and milestone payments from partners such as Roche, Bristol Myers Squibb, and Novo Nordisk, rather than from commercial product sales. Geographically, while Prothena is legally domiciled in Dublin, Ireland, its primary research, development, and technical operations are based in South San Francisco, California. The company's competitive position is strengthened by its proprietary discovery platforms and significant partnerships with major pharmaceutical companies, which provide both validation of its scientific approach and non-dilutive capital to fund its broad pipeline.
